PATIENT-REPORTED OUTCOMES CAN BE USED TO MONITOR CONTINUOUS CLINICAL RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH GOLIMUMAB: RESULTS FROM THE PURSUIT MAINTENANCE STUDY

(2) Icahn School of Medicine at Mount Sinai,New York,United States

(3) Robarts Research Institute, University of Western Ontario,London,Canada

(4) Janssen R&D, LLC,Spring House,United States

(5) Alfred Hospital,Melbourne,Australia

(6) University of California San Diego,La Jolla,United States

(7) Merck & Co., Inc.,Kenilworth,United States

(8) MSD Switzerland,Luzern,Switzerland

(9) University Hospital Gasthuisberg,Leuven,Belgium



This item was part of UEG Week 2015

This item can be cited as: United European Gastroenterology Journal; 2015: 2 (Supplement 1)